Sign inJoin waitlistJoin the waitlist

Gulam A. Manji

Director of Gastrointestinal Medical Oncology · Columbia University Irving Medical Center

Credentials: · · · · ·

History

Pancreas Center · Columbia University Irving Medical Center
Present
CUMC
Present

NewYork-Presbyterian Hospital/Columbia University Medical Center
Albany Medical Center
Ross University School of Medicine

Research

PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing
Journal of Biological Chemistry · 2002 · 317 citations
Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-kappaB and caspase-1
FEBS Letters · 2002 · 246 citations
PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B
Journal of Biological Chemistry · 2002 · First of 13 authors · 224 citations

Alexander Raufi
13 papers · 4 as a fellow
John Chabot
12 papers
MM
Michael May
12 papers · 10 as a resident
Susan Bates
12 papers
Michael Kluger
10 papers
WW
Winston Wong
10 papers · 4 as a fellow
Alina Iuga
8 papers
Beth Schrope
7 papers
Gary Schwartz
7 papers
Paul Oberstein
6 papers
Hanina Hibshoosh
5 papers
JJ
Jacob Jamison
5 papers · 1 as a resident

Grants

Targeting Cell Regulatory States to Complement MEK/Autophagy Inhibition in Pancreatic Cancer
National Cancer Institute · R01
PI · $2.3M · Columbia University Health Sciences
2022–2027
Elucidation and Targeting of Paracrine Cascades in PDAC
National Cancer Institute · U01
PI · $4.9M · Columbia University Health Sciences
2022–2027
Phase 2 Study of Combination Therapy with PLX3397 and Sirolimus to Target Tumor-Associated Macrophages in Malignant Peripheral Nerve Sheath Tumors
Food and Drug Administration · R01
Contact PI · $1.9M · Columbia University Health Sciences
2017–2024

Clinical trials

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
Principal investigator · Recruiting · Phase 2
Gulam Manji
2024–2027
RNA Precision Oncology in Advanced Pancreatic Cancer
Principal investigator · Terminated
Columbia University
2020–2023
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Principal investigator · Active not recruiting · Phase 2
Columbia University
2020–2028
Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
Principal investigator · Terminated · Phase 1, Phase 2
Columbia University
2020–2022